Latest:

Fat Pitch Financials

Special situation stocks and value investing

Stock Quote

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics Inc (NQ: RLAY )

10.75 -0.41 (-3.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Relay Therapeutics Inc

The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
From Relay Therapeutics, Inc.
Via GlobeNewswire
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs... 
Via FinancialNewsMedia
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
Relay Therapeutics to host conference call following AACR presentation 
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Guggenheim Healthcare Talks | Oncology Day
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce Third Quarter 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Foundation Medicine and Relay Therapeutics Collaborate to Develop FoundationOne®CDx as a Companion Diagnostic for Relay’s Investigational FGFR2 Inhibitor, RLY-4008
From Foundation Medicine
Via Business Wire
Relay Therapeutics to Announce Second Quarter 2022 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.